Microplastics in Your Arteries: An Emerging Cardiovascular Risk We Can No Longer Ignore

August 10, 2026

Contributing Authors: Team TRILITY / ACEND

Emerging research links microplastics in arteries and blood with inflammation and cardiovascular risk. Learn what scientists know and how ACEND addresses plastic exposure responsibly today.

For years, microplastics were discussed primarily as an environmental problem—particles contaminating oceans, soil, food, drinking water, and the air around us.

That conversation is changing rapidly.

Scientists are now finding microplastics and even smaller nanoplastics inside the human body: in blood, lungs, liver, kidneys, placenta, brain tissue, cardiovascular tissue, and perhaps most concerningly, inside atherosclerotic plaque accumulating within human arteries.

The cardiovascular implications may be significant.

A landmark human study published in The New England Journal of Medicine found that people whose carotid artery plaques contained detectable microplastics or nanoplastics experienced a substantially higher rate of heart attack, stroke, or death during approximately three years of follow-up than patients whose plaques did not contain detectable plastic particles.

More recently, research published in the European Heart Journal in July 2026 detected micro- and nanoplastics directly in the coronary circulation—the blood flowing through the vessels supplying the heart. Plastic particles were detected in 84% of patients experiencing an acute heart attack, compared with 40% of patients with chronic ischemic heart disease and 32% of patients with normal coronary arteries.

These studies do not yet prove that microplastics cause cardiovascular disease.

But they make one thing increasingly difficult to dismiss: microplastic exposure is no longer simply an environmental issue. It is becoming a human-health issue—and potentially a cardiovascular one.

At TRILITY and ACEND, we believe this emerging evidence deserves serious attention.

Microplastics in Arteries: What Researchers Found

One of the most important studies to date was published in 2024 by Marfella and colleagues in The New England Journal of Medicine.

Researchers studied patients undergoing carotid endarterectomy, a surgical procedure used to remove atherosclerotic plaque from carotid arteries.

Among 257 patients who completed approximately 34 months of follow-up, polyethylene was detected in many of the removed plaques, while polyvinyl chloride was also identified in a smaller proportion. Patients whose arterial plaques contained detectable micro- or nanoplastics had a 4.53-fold higher adjusted risk of experiencing the study’s composite endpoint of myocardial infarction, stroke, or death from any cause.

Importantly, this was an association—not proof that the plastic caused those cardiovascular events.

But the researchers found more than statistical associations.

Microscopic analysis revealed foreign particles embedded within the plaques, including particles associated with macrophages—immune cells intimately involved in inflammation and atherosclerosis. Plaques containing plastics also demonstrated evidence of heightened inflammatory activity.

That finding immediately raised an important biological question:

Could microplastics become another contributor to the inflammatory environment that makes atherosclerotic plaque dangerous?

We do not yet have a definitive answer. But accumulating mechanistic evidence suggests the question is scientifically reasonable.

Now Microplastics Have Been Found in Blood Supplying the Heart

Research published in July 2026 moves the discussion another step forward.

Investigators studying 61 patients undergoing coronary angiography measured micro- and nanoplastics in blood collected from the coronary circulation and elsewhere in the body.

Detection differed dramatically between patient groups:

84% of patients suffering ST-elevation myocardial infarction had detectable micro- or nanoplastics.

That compared with 40% among patients with chronic coronary disease and 32% among patients whose coronary arteries appeared normal.

Polyethylene—the polymer extensively used in packaging and consumer products—was the most common plastic detected.

The researchers also reported higher inflammatory markers, including tumor necrosis factor-alpha and interleukin-6, alongside the presence of micro- and nanoplastics. Smoking and long-term exposure to fine particulate air pollution were also strongly associated with their detection.

Again, this study cannot demonstrate that plastic particles caused the heart attacks.

The sample was relatively small, and environmental exposures such as smoking and air pollution may influence both cardiovascular risk and microplastic exposure.

Nevertheless, when this finding is viewed alongside the earlier carotid-plaque research, a pattern is beginning to emerge.

Plastic particles are being detected where cardiovascular disease is occurring.

Why Might Microplastics Affect the Cardiovascular System?

Atherosclerosis is far more biologically complex than simply having “too much cholesterol.”

It involves endothelial dysfunction, lipid accumulation, oxidative stress, immune activation, macrophage activity, inflammation, vascular remodeling, plaque formation, and—in dangerous cases—plaque destabilization and thrombosis.

Many of these same pathways are being investigated in microplastic research.

A 2025 systematic scoping review published in the Journal of Exposure Science & Environmental Epidemiologyanalyzed 46 studies examining micro- and nanoplastics and the cardiovascular system. Researchers identified plastics in human atherosclerotic plaques, thrombi, cardiovascular tissues and blood. Experimental evidence also implicated mechanisms including endothelial injury, oxidative LDL modification, foam-cell development, apoptosis and alterations in coagulation.

A major review published in the European Heart Journal similarly described experimental evidence that micro- and nanoplastics may promote oxidative stress, platelet aggregation, inflammatory signaling, endothelial dysfunction and cellular senescence—mechanisms already recognized as relevant to cardiovascular disease.

The emerging hypothesis is therefore not that a plastic fragment simply “blocks” an artery.

The concern is more sophisticated.

Very small particles—especially nanoplastics—may interact with immune cells, endothelial cells, lipids and vascular tissues in ways that potentially influence the biological environment in which vascular disease develops.

The Smallest Plastic Particles May Matter Most

Microplastics are generally defined as plastic particles smaller than 5 millimeters, while nanoplastics occupy the much smaller end of the spectrum, commonly below approximately 1 micrometer depending on the definition used.

Size matters because the smallest particles may behave very differently from visible fragments of plastic.

Nanometer-scale particles may cross biological barriers, enter circulation and interact with tissues in ways that larger particles cannot.

This concern gained additional support from a 2025 Nature Medicine study examining human brain, liver and kidney tissue.

Researchers confirmed micro- and nanoplastics in all three organs using multiple analytical techniques. Brain tissue contained particularly high concentrations, with electron microscopy revealing predominantly nanoscale, shard-like plastic fragments. Researchers also found higher concentrations in 2024 tissue samples compared with samples collected in 2016.

The authors emphasized that the health consequences remain uncertain.

That uncertainty is important.

Finding a substance in human tissue does not automatically mean it is causing disease.

But demonstrating that plastic particles can enter circulation, accumulate in tissues and appear within vascular lesions changes the scientific conversation dramatically.

Microplastics May Be Part of the “Exposome”

Medicine has traditionally focused heavily on familiar cardiovascular risk factors:

high LDL cholesterol, hypertension, insulin resistance, diabetes, smoking, obesity, sedentary behavior and genetics.

Those factors remain critically important.

However, researchers are increasingly studying the exposome—the cumulative collection of environmental exposures encountered throughout life.

Air pollution, heavy metals, endocrine-disrupting chemicals and now micro- and nanoplastics may represent another layer of cardiovascular stress that interacts with traditional metabolic risks.

A 2024 European Heart Journal review characterized micro- and nanoplastics as a potential emerging cardiovascular risk factor while emphasizing the need for large prospective studies capable of establishing exposure levels, tissue accumulation, dose-response relationships and ultimately causation.

That is the scientifically appropriate position today:

Concern is justified. Causation is not yet established. Exposure reduction is nevertheless a rational precautionary strategy.

Where Does Microplastic Exposure Come From?

Completely avoiding microplastics is probably unrealistic in the modern environment.

Particles have been documented in air, water, food and human tissues, and exposure can occur through ingestion and inhalation.

Potential sources include degradation of larger plastics, synthetic textiles, food and beverage packaging, bottled beverages, industrial processing, airborne pollution and ordinary consumer products.

Heat, mechanical abrasion, aging and environmental degradation can progressively fragment plastic materials into smaller particles.

That means microplastic mitigation cannot depend on one lifestyle change.

It requires thinking about cumulative exposure.

Practical steps may include reducing unnecessary use of plastic food containers, particularly for hot foods and beverages; choosing glass, stainless steel or ceramic where practical; reducing reliance on disposable bottled beverages; limiting unnecessary plastic packaging; and supporting manufacturing and packaging systems designed to minimize plastic contact.

No individual strategy eliminates exposure.

But reducing repeated sources may lower cumulative burden while science continues to determine what level of exposure carries meaningful human-health risk.

Why TRILITY and ACEND Take Microplastics Seriously

For TRILITY and ACEND, microplastic mitigation is not being treated as an environmental marketing slogan.

We believe it should become part of how health and nutrition products are formulated, manufactured, tested and packaged.

ACEND products have already achieved Microplastic Neutral Certification, and TRILITY is moving toward Microplastic-Free Certification across the ACEND product line.

Our future product strategy also increasingly incorporates Boardio paper-based packaging, reducing dependence on conventional plastic supplement canisters.

This matters because consumers taking medical foods or nutraceuticals frequently use those products every day—sometimes for months or years.

If a company develops products intended to support health, we believe minimizing unnecessary plastic exposure associated with those products should be part of the responsibility that comes with manufacturing them.

Within medical foods and nutraceuticals, TRILITY and ACEND are taking a deliberately comprehensive approach: ingredient and finished-product considerations, independent microplastic certification and reduced-plastic packaging are being addressed together.

We believe that approach places TRILITY and ACEND at the forefront of microplastic mitigation within our category.

Beyond Packaging: The Next Question Is Biological Resilience

Reducing incoming exposure is only one side of the microplastic problem.

Scientists are now asking additional questions:

How do microplastics cross intestinal and pulmonary barriers?

Why do some particles enter circulation?

Where do they accumulate?

How does the immune system respond?

Can they be eliminated?

Do particle size and polymer chemistry influence toxicity?

Could supporting barrier integrity, inflammatory regulation, antioxidant defense, gastrointestinal function and normal elimination pathways influence the biological response to microplastic exposure?

These are precisely the questions that need rigorous study.

TRILITY’s work in this area increasingly extends beyond packaging toward understanding the biological systems involved in microplastic exposure, barrier integrity, inflammatory balance, detoxification and elimination.

Importantly, nutritional interventions should not currently be described as proven methods of removing microplastics from human arteries. That evidence does not yet exist.

The opportunity is to build scientifically disciplined strategies around what biology tells us while continuing to test what actually works.

Chronic Inflammation May Be an Important Intersection

This research is particularly relevant to ACEND because inflammation sits at the intersection of many chronic diseases.

Atherosclerosis itself is an inflammatory disease of the arterial wall.

Micro- and nanoplastic research repeatedly identifies oxidative stress, endothelial dysfunction, immune activation and inflammatory signaling as possible biological mechanisms of harm.

ACEND-CI was developed for the dietary management of chronic inflammation and systemic inflammatory balance.

That does not mean ACEND-CI has been demonstrated to remove microplastics or prevent microplastic-associated cardiovascular disease.

Instead, it reflects the broader systems-based philosophy behind ACEND: chronic health challenges often emerge from interactions among inflammatory, metabolic, vascular, gastrointestinal and cellular pathways rather than from a single isolated mechanism.

Microplastic exposure may eventually become another environmental variable within that systems model.

What We Still Need to Learn

The science of microplastics and cardiovascular disease is advancing rapidly, but major questions remain.

Researchers need standardized methods for detecting extremely small particles while preventing laboratory contamination. Larger prospective human studies are required. Scientists need better measures of actual lifetime exposure and better understanding of which polymers, particle sizes and concentrations matter most.

We also need intervention studies.

If exposure is reduced, does the microplastic concentration in blood decline?

Can the body clear accumulated particles?

How long does clearance take?

Can microplastics already embedded in vascular tissue be removed?

Does lowering exposure improve cardiovascular biomarkers or outcomes?

Those questions remain unanswered.

The appropriate response is therefore neither panic nor indifference.

It is precaution combined with rigorous science.

The Evidence Is Moving Faster Than Many Expected

Only a few years ago, the idea of plastic particles accumulating inside human arteries would have sounded extraordinary.

Today, micro- and nanoplastics have been detected in human atherosclerotic plaques, cardiovascular tissues, thrombi and circulating blood. Human observational studies have associated their presence with cardiovascular disease and adverse cardiovascular outcomes, while laboratory research provides plausible mechanisms involving inflammation, oxidative stress, endothelial injury and thrombosis.

That still does not establish microplastics as a confirmed cause of cardiovascular disease.

But waiting for every mechanistic question to be resolved before reducing unnecessary plastic exposure would make little sense.

For TRILITY and ACEND, the direction is clear.

We intend to reduce plastic where we can, independently verify what is in our products, rethink conventional nutraceutical packaging, investigate the biological consequences of microplastic exposure and continue following the science as it develops.

Because a company developing products for human health should not consider the material surrounding the product irrelevant to the health of the person taking it.

Therefore, our position is straightforward: microplastic exposure deserves serious scientific attention, responsible mitigation and far greater consideration throughout the medical-food and nutraceutical industries.

References

Marfella R, et al. Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. New England Journal of Medicine. 2024;390:900-910. Read the study
Paolisso P, et al. Micro- and nano-plastics in the coronary circulation and air pollution exposure in ischaemic heart disease. European Heart Journal. 2026. Read the study
Prattichizzo F, et al. Micro-nanoplastics and cardiovascular diseases: evidence and perspectives. European Heart Journal. 2024;45:4099-4110. Read the review
Goldsworthy A, et al. Micro-nanoplastic induced cardiovascular disease and dysfunction: a scoping review.Journal of Exposure Science & Environmental Epidemiology. 2025;35:746-769. Read the review
Nihart AJ, et al. Bioaccumulation of microplastics in decedent human brains. Nature Medicine.2025;31:1114-1119. Read the study
Yang Y, et al. Multimodal detection and analysis of microplastics in human thrombi. Peer-reviewed human thrombus research indexed in PubMed, 2024. View the study record
Leonard SVL, et al. Microplastics in human blood: Polymer types, concentrations and characterization.2024. View the study record

Note: Always consult with a healthcare professional before considering any treatment options or significant dietary changes.